Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Academic and Community Cancer Research United
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04197687CT.gov TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery | — | Unknown | — | — | — |
NCT03199885CT.gov Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01730833CT.gov Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pertuzumab (this asset) | Academic and Community Cancer Research United | P3 | BB · 64 |
| Cyclophosphamide | Second Affiliated Hospital, School of Medicine, Zhejiang University | P3 | BB |
| Adriamycin | Virginia Commonwealth University | P3 | BB |
| Letrozole | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | P4 | BB |
| Trastuzumab | Academic and Community Cancer Research United | P3 | BB |
| Carboplatin | Genmab | P3 | BB |
| Pembrolizumab | Genmab | P2 | BB |
| Eribulin Monomethanesulfonate | Montefiore Medical Center | P3 | BB |
| Tamoxifen | National Cancer Institute (NCI) | P3 | B |
+42 more in the Breast Adenocarcinoma cohort
Other indications for Pertuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P3 | BBB · 75 |
| Inflammatory Breast Carcinoma | — | P3 | BBB · 72 |
| Breast Cancer | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pertuzumab in Breast Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-neu-receptor-human-mouse-monoclonal-2c4-heavy-chain-disulfide-with-human-mouse-monoclonal-2c4-kappa-chain-dimer-breast-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →